211 related articles for article (PubMed ID: 17704241)
1. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
3. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
4. Identification and evaluation of a new tumor cell-binding peptide, FROP-1.
Zitzmann S; Krämer S; Mier W; Hebling U; Altmann A; Rother A; Berndorff D; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Jun; 48(6):965-72. PubMed ID: 17504878
[TBL] [Abstract][Full Text] [Related]
5. PEGylation enables the specific tumor accumulation of a peptide identified by phage display.
Mier W; Krämer S; Zitzmann S; Altmann A; Leotta K; Schierbaum U; Schnölzer M; Eisenhut M; Haberkorn U
Org Biomol Chem; 2013 Apr; 11(16):2706-11. PubMed ID: 23474823
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
7. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of a peptide with affinity to head and neck cancer.
Nothelfer EM; Zitzmann-Kolbe S; Garcia-Boy R; Krämer S; Herold-Mende C; Altmann A; Eisenhut M; Mier W; Haberkorn U
J Nucl Med; 2009 Mar; 50(3):426-34. PubMed ID: 19223422
[TBL] [Abstract][Full Text] [Related]
9. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues.
Cheng Z; Chen J; Miao Y; Owen NK; Quinn TP; Jurisson SS
J Med Chem; 2002 Jul; 45(14):3048-56. PubMed ID: 12086490
[TBL] [Abstract][Full Text] [Related]
10. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.
Kumar SR; Deutscher SL
J Nucl Med; 2008 May; 49(5):796-803. PubMed ID: 18413389
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of (111)In-labeled macrocyclic chelator-amino acid derivatives for cancer imaging.
Lee JJ; Shetty D; Lee YS; Kim SE; Kim YJ; Hong MK; Son JY; Jeong JM
Nucl Med Biol; 2012 Apr; 39(3):325-33. PubMed ID: 22136890
[TBL] [Abstract][Full Text] [Related]
12. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
13. Challenges in optimizing a prostate carcinoma binding peptide, identified through the phage display technology.
Askoxylakis V; Zitzmann-Kolbe S; Zoller F; Altmann A; Markert A; Rana S; Marr A; Mier W; Debus J; Haberkorn U
Molecules; 2011 Feb; 16(2):1559-78. PubMed ID: 21321528
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the RGD Motif-Containing α
Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
[TBL] [Abstract][Full Text] [Related]
15. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.
Bailey GA; Price EW; Zeglis BM; Ferreira CL; Boros E; Lacasse MJ; Patrick BO; Lewis JS; Adam MJ; Orvig C
Inorg Chem; 2012 Nov; 51(22):12575-89. PubMed ID: 23106422
[TBL] [Abstract][Full Text] [Related]
16. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
17. Tumor targeting by an aptamer.
Hicke BJ; Stephens AW; Gould T; Chang YF; Lynott CK; Heil J; Borkowski S; Hilger CS; Cook G; Warren S; Schmidt PG
J Nucl Med; 2006 Apr; 47(4):668-78. PubMed ID: 16595502
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, and biological evaluation of (99m) Tc(CO)3 -labeled peptides for potential use as tumor targeted radiopharmaceuticals.
Baishya R; Nayak DK; Chatterjee N; Halder KK; Karmakar S; Debnath MC
Chem Biol Drug Des; 2014 Jan; 83(1):58-70. PubMed ID: 23679852
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties.
Chen J; Cheng Z; Owen NK; Hoffman TJ; Miao Y; Jurisson SS; Quinn TP
J Nucl Med; 2001 Dec; 42(12):1847-55. PubMed ID: 11752084
[TBL] [Abstract][Full Text] [Related]
20. H4octapa: an acyclic chelator for 111In radiopharmaceuticals.
Price EW; Cawthray JF; Bailey GA; Ferreira CL; Boros E; Adam MJ; Orvig C
J Am Chem Soc; 2012 May; 134(20):8670-83. PubMed ID: 22540281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]